Retroviral Integrase: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
==Introduction== | ==Introduction== | ||
Integrase is an essential retroviral enzyme that binds to viral DNA and inserts it into a host cell chromosome. It is produced by a class of retrovirus (like HIV) and is used by the virus to incorporate its genetic material into the host cell DNA. The host cellular machinery then produces mRNA and then protein from the incorporated genetic material, thus replicating the virus. Although several integrase inhibiting drugs have been investigated, the mechanism of action was not clear. On February 1st, 2010, a crystal structure of the PFV Intasome was published, paving the way for better retroviral treatments. | Integrase is an essential retroviral enzyme that binds to viral DNA and inserts it into a host cell chromosome. It is produced by a class of retrovirus (like HIV) and is used by the virus to incorporate its genetic material into the host cell DNA. The host cellular machinery then produces mRNA and then protein from the incorporated genetic material, thus replicating the virus. Although several integrase inhibiting drugs have been investigated, the mechanism [responsible for strand-transfer inhibition action remain unclear] of action was not clear. On February 1st, 2010, a crystal structure of the PFV Intasome was published, paving the way for better retroviral treatments. [However, Hare ''et al'' (2010) determined the structural constituents of retroviral integration. Further elucidation of the complete structure of the retroviral integrase, and its application to regulate functional and enzymatic activities could potentially enable researchers to delay the progression of and provide the next best medical treatment for retroviral diseases. | ||
HIV Integrase inhibitors: Raltegravir, marketed as Isentress is currently approved as a therapeutic inhibitor of HIV integrase. It was approved on October 12, 2007. | HIV Integrase inhibitors: Raltegravir, marketed as Isentress is currently approved as a therapeutic inhibitor of HIV integrase. It was approved on October 12, 2007. | ||
==PFV Crystalization== | ==PFV Crystalization== | ||
